Wassil Jim sold $15K of PCVX
Wassil Jim (CHIEF OPERATING OFFICER) sold 301 shares of Vaxcyte, Inc. (PCVX) at $50.26 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental sentiment information but does not change the company’s fundamentals or introduce new catalysts.
Market read
Expect limited market reaction; treat as low-signal unless paired with additional insider activity or new clinical/regulatory updates.
What to watch
Traders may over-weight small insider sales; the more actionable signal would be a cluster of sales/buys outside 10b5-1 or any concurrent fundamental news.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Vaxcyte, Inc.
Ticker impact
Vaxcyte COO Wassil Jim sold 301 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.
Likely limited/short-lived impact; watch for follow-on insider activity or other catalysts.
The filing is a routine Form 4 with a stated 10b5-1 plan; the disclosed sale size is small relative to typical liquidity, and no new company fundamentals are introduced.
Market effects
Minimal; this is company-specific insider transaction disclosure with no stated operational/clinical/regulatory change.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerVaxcyte, Inc.
Subject of the SEC Form 4 insider transaction disclosure.
- insiderWassil Jim
Chief Operating Officer who sold shares under a pre-arranged 10b5-1 plan.
